Twist Bioscience (NASDAQ:TWST) CFO Adam Laponis Sells 2,462 Shares of Company Stock

Twist Bioscience Corporation (NASDAQ:TWST) CFO Adam Laponis sold 2,462 shares of the business’s stock in a transaction dated Friday, October 9th. The shares were sold at an average price of $156.30, for a total value of $384,810.60. Following the completion of the transaction, the chief financial officer owned 98,114 shares in the company, valued at $15,335,218.20. The trade was a 2.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Adam Laponis also recently made the following trade(s):

• On Friday, October 2nd, Adam Laponis sold 8,057 shares of Twist Bioscience stock. The stock was sold at an average price of $188.88, for a total value of $1,521,806.16.

Twist Bioscience Price Performance

Shares of NASDAQ:TWST traded down $0.53 during trading on Tuesday, hitting $151.33. 1,528,138 shares of the company’s stock were exchanged, compared to its average volume of 1,708,576. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. Twist Bioscience Corporation has a 52-week low of $23.30 and a 52-week high of $219.71. The business’s 50-day simple moving average is $145.34 and its 200 day simple moving average is $97.50. The company has a market cap of $9.49 billion, a price-to-earnings ratio of -68.17 and a beta of 2.19.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business had revenue of $118.38 million for the quarter, compared to the consensus estimate of $114.55 million. During the same period last year, the business posted $0.33 EPS. The firm’s revenue for the quarter was up 23.2% compared to the same quarter last year. As a group, equities analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Sivik Global Healthcare LLC purchased a new position in shares of Twist Bioscience in the third quarter valued at $218,000. Fermata Advisors LLC purchased a new stake in Twist Bioscience during the third quarter valued at $243,000. GAMMA Investing LLC raised its stake in Twist Bioscience by 40.7% during the third quarter. GAMMA Investing LLC now owns 1,327 shares of the company’s stock valued at $256,000 after purchasing an additional 384 shares in the last quarter. Veracity Capital LLC purchased a new stake in Twist Bioscience during the third quarter valued at $726,000. Finally, QRG Capital Management Inc. bought a new position in Twist Bioscience during the second quarter valued at $277,000.

Analyst Upgrades and Downgrades

TWST has been the subject of several research analyst reports. Leerink Partners raised their target price on shares of Twist Bioscience from $160.00 to $190.00 and gave the company an “outperform” rating in a research note on Tuesday, September 29th. UBS Group initiated coverage on shares of Twist Bioscience in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $144.00 price target on the stock. Barclays boosted their price target on shares of Twist Bioscience from $112.00 to $215.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 7th. BWS Financial reissued a “sell” rating and set a $45.00 price objective on shares of Twist Bioscience in a report on Friday, September 18th. Finally, Evercore lowered Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price objective for the company. in a research report on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $143.67.

About Twist Bioscience

Twist Bioscience Corporation (NASDAQ:TWST) is a biotechnology company that develops and manufactures synthetic DNA using a silicon-based production platform. Its technology is designed to enable the precise, high-throughput synthesis of DNA at smaller scale and with potentially lower material consumption than traditional methods.

The company provides synthetic DNA products and services for applications in drug discovery and development, biotechnology research, agriculture, industrial chemicals and other life sciences markets.